Bioventix plc
(“Bioventix” or the “Company”)
Appointment of
CFO
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, announces that
Bruce Hiscock will join the Board as
Chief Financial Officer with immediate effect.
Mr Hiscock was previously CEO and CFO of everyLIFE Technologies,
a technology business delivering digital care planning solutions to
social care providers. Prior to this he was the Managing Director
of MITIE Security Systems, the CEO of Protec plc, an AIM listed
security and technology services business, and held several CFO
roles at both fast-growing listed and private companies over a
30-year career. Mr Hiscock is a member of the Institute of
Chartered Accountants of Scotland.
The following information regarding the appointment of
Bruce Edward Heath Hiscock (aged 61)
is required to be disclosed under Schedule 2(g) of the AIM Rules
for Companies:
| Current directorships and/or
partnerships |
Former
directorships and/or partnerships
(within the last five years) |
| n/a |
everyLIFE Technologies
Limited
Warnborough Associates Limited |
There are no further disclosures to be made under Schedule 2(g)
of the AIM Rules for Companies.
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.
